CRBP Corbus Pharmaceuticals, Inc. Earnings per share for the last twelve months

CRBP (Corbus Pharmaceuticals Holdings, Inc.) - company brandmark

Risks for Corbus Pharmaceuticals (CRBP) are linked to the pivot from mergers toward antibody partnerships, which confirms the 12-month EPS trend on the GURU.Markets chart, where the value -6.07 expresses the state of the metric. Stability is provided by the monetization of inflammation research with pharma behemoths, while patents for targeted therapy with low production costs guarantee potential profit growth.

CRBP (Corbus Pharmaceuticals) Net earnings per share for the last 12 months history from 07/04/2022 to 11/17/2026

Corbus Pharmaceuticals, Inc. - analytical breakdowns and key metrics (CRBP)

Basic company analysis:corbuspharma.com (CRBP)
Mass-produced product of Corbus Pharma

The development of the antibody-drug conjugate CRB-701 and the advancement of its oncology portfolio define the financial profile of Corbus Pharmaceuticals (CRBP). An analysis of the company's trailing 12-month net profit per share allows for an assessment of the real return per share, stripped of one-time factors, which helps investors differentiate fundamental business resilience from speculative market noise when evaluating capitalization prospects.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months cardiffoncology.com|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla, Inc. BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharmaceuticals, Inc. CTXR|Net earnings per share for the last 12 months CLRB (Cellectar Biosciences)|BLRX (BioLineRx) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months